Sorrento Gains CE Mark for Its Covistix COVID-19 Antigen Test
Sorrento Therapeutics has received a CE mark for its Covistix COVID-19 virus rapid antigen detection test.
The test can detect the SARS-CoV-2 virus nucleocapsid antigen in nasal or nasopharyngeal samples. A large study in Mexico demonstrated that the test has 81 percent sensitivity in correctly identifying infected individuals, according to the San Diego, Calif.-based company.
The text currently has an Emergency Use Authorization (EUA) in Mexico, and Sorrento has filed for additional EUAs in the U.S., Canada, Brazil and with the World Health Organization.